SYNBIOTICS CORPORATION EXHIBIT 11.1
------------
COMPUTATION OF EARNINGS (LOSS) PER SHARE
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------- -------------
1995 1994 1995 1994
---- ---- ---- ----
PRIMARY EARNINGS (LOSS) PER SHARE:
Net income (loss) per statement of operations $ (854,000) $ 1,188,000 $ 880,000 $ 323,000
============ ============= ============ ============
Weighted average number of shares outstanding 5,809,000 5,824,000 5,827,000 5,857,000
============ ============= ============ ============
Primary earnings (loss) per share $ (.15) $ .20 $ .15 $ .06
============ ============= ============ ============
FULLY DILUTED EARNINGS (LOSS) PER SHARE:/(1)/
Net income (loss) per statement of operations $ (854,000) $ 1,188,000 $ 880,000 $ 323,000
============ ============= ============ ============
Reconciliation of weighted average number of
shares per primary computation above, to
amount used for fully diluted computation:
Weighted average number of shares outstanding,
per primary computation 5,809,000 5,824,000 5,827,000 5,857,000
------------ ------------ ------------ ------------
Add-effect of outstanding options (as determined
by the application of the treasury method) 54,000 7,000 8,000
------------ ------------ ------------ ------------
Weighted average number of shares, as adjusted 5,863,000 5,824,000 5,834,000 5,865,000
============ ============= ============ ============
Fully diluted earnings (loss) per share $ (.15) $ .20 $ .15 $ .06
============ ============= ============ ============
/(1)/ This computation is submitted, for the three month period ended September
30, 1995, in accordance with Regulation S-B Item 601(b)(11) although it is
contrary to paragraph 40 of APB Opinion No. 15 because it produces an
anti-dilutive result.
-1-